Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603562 · ClinicalTrials.gov registry record · Phase 1
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
A Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by aTyr Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT02603562: Completed Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by aTyr Pharma.
NCT02603562 is a Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD) that has completed, run by aTyr Pharma. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603562, a Phase 1 study of Facioscapulohumeral Muscular Dystrophy (FSHD), has completed, sponsored by aTyr Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.
Primary Outcome
TEAEs were defined as adverse events (AEs) with an onset following administration of the first dose of study drug. AEs were defined as any untoward medical occurrence in a participant administered study drug and that does not necessarily have a causal relationship with the study drug. Worsening of a pre-existing medical condition should have been considered an AE if there was either an increase in severity, frequency, or duration of the condition or an association with significantly worse outcom
Conditions Studied
Interventions
- BIOLOGICAL ATYR1940
Study Locations (7)
Other
- Centre d'nvestigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CICCPCET) - Marseille
- Institut de Myologie - Paris
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta - Milan
California
- Stanford University - Stanford
Iowa
- University of Iowa Children's Hospital - Iowa City
Ohio
- OSU Wexner Medical Center - Columbus
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2016-12-12 |
| Phase | Phase 1 |
What the finished NCT02603562 record still lists
NCT02603562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Facioscapulohumeral Muscular Dystrophy (FSHD) appearing as the primary indexed condition, and to 1 intervention - of which ATYR1940 is the first listed.
NCT02603562 lists 7 locations in 5 states (Other, California, Iowa).
Frequently Asked Questions
What is clinical trial NCT02603562 about?
NCT02603562 is a clinical study titled "Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy". The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.
What is the current status of trial NCT02603562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-03-30. Estimated completion is 2016-12-12.
What conditions does trial NCT02603562 study?
This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy (FSHD).
What interventions are being tested in trial NCT02603562?
The interventions under investigation include: ATYR1940 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02603562?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603562 being conducted?
This trial has 7 study locations across California, Iowa, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facioscapulohumeral Muscular Dystrophy (FSHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02603562's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI